Why real-world HCP insight is becoming a commercial advantage

Tern plc

Pharma companies have used healthcare professional personas for years, but many are still built on limited interviews, workshops and internal assumptions. That makes them useful for alignment, but less useful for execution. If personas do not reflect how clinicians actually think, speak and make decisions in practice, they can weaken messaging, waste spend and reduce the impact of evidence.

Traditional approaches tend to capture what healthcare professionals say in a formal research setting. They are less effective at showing what drives behaviour in real clinical environments, where time pressure, patient complexity, reimbursement issues and changing guidance all shape decisions. As a result, a persona can look credible on paper while failing to explain what really affects uptake.

If a company is working from an outdated or simplified view of its audience, it may focus on the wrong barriers, use evidence in the wrong way or miss the language that actually builds confidence.

The value here is not simply richer insight. It is better accuracy. Real-world language can reveal how clinicians frame problems, what concerns they return to, what evidence they trust and what practical issues affect action. That produces a more grounded view of the audience and gives teams a stronger basis for message development.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Pharma engagement shifts from reach to relevance

Pharma engagement is moving from broad reach to relevant messaging across connected patient journeys.

Device Authority partnership expands route into enterprise IoT security

Device Authority’s partnership with Xalient strengthens its enterprise IoT security positioning by placing KeyScaler within a managed, identity-led cybersecurity model for complex and regulated environments.

Tern increases convertible loan note investment in Talking Medicines

Tern has received £270,000 of new unsecured convertible loan notes from Talking Medicines, increasing its total convertible loan note holding to approximately £0.79 million while retaining a 23.8% equity stake.

Tern Plc invests $280,000 in Device Authority convertible loan notes

Tern has invested $280,000 in new unsecured convertible loan notes issued by Device Authority, forming part of a wider funding round of up to $1.6 million from existing investors.

Surgical training technology moves closer to the centre of precision medicine

Fundamental XR is targeting a critical adoption gap in advanced healthcare by using immersive simulation to help surgical teams prepare for complex procedures with greater consistency and scale.

GLP-1 therapies move into a wider investor debate

GLP-1 therapies are moving beyond weight loss and diabetes, creating a wider investor discussion around behaviour, risk and market positioning.

Search